• Dyne Therapeutics posted a wider GAAP net loss of USD 178.56 million for the quarter ended June 30, 2026, versus USD 110.86 million a year earlier.
• GAAP operating loss widened to USD 181.66 million from USD 115.79 million as operating expenses climbed to USD 181.66 million from USD 115.79 million.
• GAAP research and development expense rose to USD 152.17 million from USD 99.24 million, driven by higher z-rostudirsen and z-basivarsen spending.
• GAAP general and administrative costs increased to USD 29.49 million from USD 16.56 million on higher headcount and launch preparation activity.
• FDA accepted z-rostudirsen BLA for priority review with a Jan. 21, 2027 PDUFA date; Phase 3 FORZETTO started in May 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-323639), on July 29, 2026, and is solely responsible for the information contained therein.